6.
Mao S, Sun J, Gu T, Zhu F, Yin F, Zhang L
. Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case-control study. J Hum Hypertens. 2017; 31(8):530-536.
DOI: 10.1038/jhh.2017.7.
View
7.
Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S
. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2013; 63(3):520-526.
PMC: 4446717.
DOI: 10.1161/HYPERTENSIONAHA.113.01967.
View
8.
Carey R, Sakhuja S, Calhoun D, Whelton P, Muntner P
. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2018; 73(2):424-431.
PMC: 6693520.
DOI: 10.1161/HYPERTENSIONAHA.118.12191.
View
9.
Ahmed M, Nudy M, Bussa R, Filippone E, Foy A
. A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension. Eur J Intern Med. 2023; 113:83-90.
DOI: 10.1016/j.ejim.2023.04.021.
View
10.
Grassi G, DellOro R, Quarti-Trevano F, Vanoli J, Oparil S
. Sympathetic Neural Mechanisms in Hypertension: Recent Insights. Curr Hypertens Rep. 2023; 25(10):263-270.
PMC: 10505104.
DOI: 10.1007/s11906-023-01254-4.
View
11.
Mahfoud F, Schlaich M, Lobo M
. Device Therapy of Hypertension. Circ Res. 2021; 128(7):1080-1099.
DOI: 10.1161/CIRCRESAHA.121.318091.
View
12.
Acelajado M, Hughes Z, Oparil S, Calhoun D
. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019; 124(7):1061-1070.
PMC: 6469348.
DOI: 10.1161/CIRCRESAHA.118.312156.
View
13.
Thangaraj S, Oxlund C, Fonseca M, Svenningsen P, Stubbe J, Palarasah Y
. The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension. J Hypertens. 2021; 40(1):153-162.
DOI: 10.1097/HJH.0000000000002990.
View
14.
Cai A, Calhoun D
. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017; 70(1):5-9.
PMC: 5515281.
DOI: 10.1161/HYPERTENSIONAHA.117.08929.
View
15.
Noubiap J, Nansseu J, Nyaga U, Sime P, Francis I, Bigna J
. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2018; 105(2):98-105.
DOI: 10.1136/heartjnl-2018-313599.
View
16.
Virani S, Alonso A, Aparicio H, Benjamin E, Bittencourt M, Callaway C
. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143(8):e254-e743.
DOI: 10.1161/CIR.0000000000000950.
View
17.
Bisognano J, Bakris G, Nadim M, Sanchez L, Kroon A, Schafer J
. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58(7):765-73.
DOI: 10.1016/j.jacc.2011.06.008.
View
18.
Copur S, Peltek I, Mutlu A, Tanriover C, Kanbay M
. A new immune disease: systemic hypertension. Clin Kidney J. 2023; 16(9):1403-1419.
PMC: 10469084.
DOI: 10.1093/ckj/sfad059.
View
19.
Madhur M, Lob H, McCann L, Iwakura Y, Blinder Y, Guzik T
. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2009; 55(2):500-7.
PMC: 2819301.
DOI: 10.1161/HYPERTENSIONAHA.109.145094.
View
20.
Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X
. Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015; 94(14):e731.
PMC: 4554042.
DOI: 10.1097/MD.0000000000000731.
View